Biogen's Fampyra Launched In Canada Daily Markets Besides BG-12, Biogen is developing other multiple sclerosis candidates like daclizumab, in partnership with Abbott Labs (NYSE:ABT), and PEGylated interferon. Biogen recently signed an exclusive, worldwide option and collaboration agreement with ... |
